Stephen Squinto, Life Sciences Private Capital chief investment officer and managing partner

December 15, 2023 06:00 AM EST

Q&A: JP Morgan’s new life sciences private capital leader on the bank’s expanding ambitions, vetting startups and Abu Dhabi’s biotech push

Amber Tong

Longtime biotech entrepreneur and investor Stephen Squinto helped build biotech giants Regeneron and Alexion before moving to the investment world at OrbiMed Advisors. Now, one …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Q&A: JP Morgan’s new life sciences private capital leader on the bank’s expanding ambitions, vetting startups and Abu Dhabi’s biotech push

Amber Tong

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Sofinnova outlines $550M fund after IPOs and M&A deals

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

Accelerated approval brings Pfizer's BRAF inhibitor to first-line patients

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.

GSK's Zejula-Jemperli combo in ovarian cancer hits primary endpoint, misses on overall survival

Q&A: JP Mor­gan’s new life sci­ences pri­vate cap­i­tal leader on the bank’s ex­pand­ing am­bi­tions, vet­ting star­tups and Abu Dhabi’s biotech push

Amber Tong

Sign up to read this article for free.

more like this

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

GSK's Ze­ju­la-Jem­per­li com­bo in ovar­i­an can­cer hits pri­ma­ry end­point, miss­es on over­all sur­vival

Q&A: JP Morgan’s new life sciences private capital leader on the bank’s expanding ambitions, vetting startups and Abu Dhabi’s biotech push

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Sofinnova outlines $550M fund after IPOs and M&A deals

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

Accelerated approval brings Pfizer's BRAF inhibitor to first-line patients

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.

GSK's Zejula-Jemperli combo in ovarian cancer hits primary endpoint, misses on overall survival